Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine for autism spectrum disorder symptoms
IRCT20200115046137N4Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of famotidine in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Autism severity. Started Nov 2024; status: completed.
02
Drugs
famotidine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20200115046137N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200115046137N4.